[1] General Office of the State Council. Guidelines on Improving the Centralized Procurement of Medicines in Public Hospitals.[EB/OL].(2015-02-28)[2019-12-01]. http://www.gov.cn/zhengce/content/2015-02/28/content_9502.htm. [2] General Office of the State Council. Some Opinions of the Leading Group of the State Council for Deepening the Reform of the Medical and Health Care System on Further Promoting and Deepening the Experience in the Reform of the Medical and Healthcare System[EB/OL].(2016-11-08)[2019-12-01]. http://www.gov.cn/xinwen/2016-11/08/content_5130271.htm. [3] Medical Administration and Hospital Authority. Notice on the Issuance of the First Batch of State Key Monitoring and Rational Drug Use Catalogues (Chemical Drugs and Biological Products)[EB/OL].(2019-07-01)[2019-12-01].http://www.nhc.gov.cn/yzygj/s7659/201907/d356ce8a4ba1461ca66c544724dffc5e.shtml. [4] Liang GK, Fu Y, Li JL, et al.Influence of key monitoring drugs policy on the change of adjuvant drugs in sample area[J]. Chin Pharm J(中国药学杂志), 2018, 53(18): 1613-1618. [5] Li J, Wang ZC, Li J, et al.Optimize drug management through drug budgets under the new medical reform[J]. Clinical Medication Journal(临床药物治疗杂志), 2018, 16(11): 20-22. [6] Sun MR, Wang LY, Qian CY, et al.Practice of management and control of rational adjuvant drug use in our hospital[J]. China Pharm(中国药房), 2018, 29(17): 2310-2314. [7] National Health Commission. Notification on the Implementation Of Drug Use Monitoring and Comprehensive Clinical Evaluation[EB/OL].(2019-04-03)[2019-12-01]. http://cdsip.nhfpc.gov.cn/work/show18341.html. [8] Zhao QG, Sun L.Application of multidisciplinary collaboration combined with clinical pharmacist intervention in adjuvant medication management[J]. J Community Med(社区医学杂志), 2018, 16(7): 79-80. [9] Tang HL, Zhang T, Liu F, et al.An exploratory study on the method and process of evidence-based evaluation of off-label drug use[J]. Chin Pharm J(中国药学杂志), 2015, 50(19): 1735-1738. [10] Zhang W, Wang L, Zhao YL, et al.Assessment of off-label use of alprostadil injection by evidence-based approach[J]. Chin J Hosp Pharm(中国医院药学杂志), 2017, 37(2): 177-180. [11] Health and Family Planning Commission of Anhui Provinc. Notice of Anhui Province on improving the monitoring and early warning management system for key drugs in 2018[EB/OL].(2018-06-26)[2019-12-01]. http://www.chinaemed.com/Province/anhui/Docs/Policy/Policy/11911. [12] Liang GK, Qin SB, Li JL, et al.Influence of key monitoring drugs policy on the change of proton pump inhibitors in sample areas[J]. Chin J Hosp Pharm(中国医院药学杂志), 2018, 38(22): 2299-2304. [13] Chen LM, He XY, Huang JS, et al.Analysis of the effectiveness of the key monitoring and management of traditional Chinese medicine injections in one hospital[J]. J Guangdong Pharm Univ(广东药科大学学报), 2019, 35(1): 116-119. [14] Xu Y, Xu WW, Li Y.Analysis of utilization of adjuvant drugs[J]. Chin J Hosp Pharm(中国医院药学杂志), 2017, 37(1): 73-75. [15] Huang Q, Zhang Z, Liu LH.Analysis of 45 cases of adverse drug reaction induced by alprostadil[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2014, 11(5): 304-308. [16] Hu PZ, Ma L, Guo DH, et al.Automatic surveillance for hemoc-ytopenia caused by cinepazide maleate[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2016, 13(12): 745-752. [17] Zhang YY, Wu CF, Wu ZY, et al.Practice of adjuvant drugs control based on information platform[J]. Chinese Hospital Management(药事管理), 2018, 38(5): 54-55. [18] Deng JX, Wang L, Chen WG, et al.Research and application of adverse drug reaction rapid reporting and intelligent searching system based on HIS[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2015, 12(12): 731-734. |